Oppenheimer Initiates Coverage On Opus Genetics with Outperform Rating, Announces Price Target of $10

Benzinga Newsdesk www.benzinga.com Positive 53.1%

Neg 0% Neu 0% Pos 53.1%

Oppenheimer analyst Andreas Argyrides initiates coverage on Opus Genetics (NASDAQ:IRD) with a Outperform rating and announces Price Target of $10.